PFM39 (SML1839) is a small molecule that specifically inhibits exonuclease activity of MRE11, binds in the active site similar to mirin, inhibits dsDNA end resection in A549 cells with IC50 of 50-75 uM, inhibits HR without significantly increasing NHEJ..

PfKRS1 inhibitor 5 is a potent, selective, oral inhibitor of P. falciparum lysyl-tRNA synthetase (PfKRS1) with IC50 of 15 nM, displays >100-fold selectivity over Human KRS (HsKRS, IC50=1.8 uM).

PFE-360 is a novel potent, selective, brain-penetrating LRRK2 inhibitor with IC50 of 3 nM.

PF-9184 is a potent, selective mPGES-1 (microsomal prostaglandin E synthase-1) inhibitor with IC50 of 16.5 nM.

PF-6808472 (XO44) is a sulfonyl fluoride chemical probe that covalently labels a broad swath of the intracellular kinome with high efficiency.

PF-6689840 (PF6689840) is a potent and selective Type II PTK6/Brk inhibitor with IC50 of 54 nM in biochemical assays.

PF-4776548 (PF-04776548) novel HIV integrase inhibitor for treatment of HIV infections..

PF-4363467 (PF 04363467) is a novel highly potent, brain penetrant dopamine D3/D2 receptor antagonist with Ki of 1.3/692 nM respectively, with high selectivity for D3R versus other biogenic amine receptors.

PF-3893787 (ZPL 3893787) is a potent and selective H4 receptor antagonist with binding Ki of 2.4 nM.

PF3845yne is a Alkyne analogues of PF3845.

PF-3635659 (PF-03635659) is a potent, very long dissociative half-life (slow off-rate, >1440 min) muscarinic M3 antagonist with Ki of 0.2 nM, shows potential for the treatment of chronic obstructive pulmonary disease (COPD)..

PF-232798 (PF-00232798) is a potent CCR5 antagonist with IC50 of <0.1 nM in gp160 fusion assay, exhibits potent broad-spectrum anti-HIV-1 activity.

PF-219061 (PF 219061, PF219061) is a potent, selective agonist of dopamine D3 receptor with EC50 of 8 nM.

PF-184298 is a potent, selective dual serotonin and noradrenaline monoamine reuptake inhibitor (SNRI) with IC50 of 6 nM and 21 nM, respectively.

PF-152 is a potent, highly selective and orally bioavailable MMP13 inhibitor with Ki of 1.5 nM, with no activity against MMP3 (Ki>10 uM).

PF-06815345 (PF 6815345) is a potent prodrug PCSK9 modulator that inhibits PCSK9 secretion in vitro translation assay.

PF-06815189 is a potent, selective phosphodiesterase 2 (PDE2) inhibitor with IC50 of 0.4 nM, >1,000-fold selectivity over PDE5.

PF-06807656 is a potent, selective renal outer medullary potassium channel (ROMK, Kir1.1a) inhibitor with IC50 of 61 nM for hROMK in patch-clamp assays.

PF-06795071 is a potent, selective, covalent Monoacylglycerol Lipase (MAGL) inhibitor with IC50 of 3 nM, >1,000-fold selectivity over FAAH.

PF-06751979 is a potent, selective, brain penetrant BACE1 inhibitor with binding IC50 of 7.3, 27-fold selectivity over BACE2.

PF-06679142 is a novel potent, orally active, α1β1γ1/α2β1γ1-isoform selective AMPK activator with Kd of 14 nM, EC50 of 22 nM for α1β1γ1-AMPK, shows minimal activity at the β2-containing isoforms (α1β2γ1, α2β2γ1, α2β2γ3).

PF-06651600 malonate is a novel potent, selective JAK3 inhibitor with IC50 of 0.346 nM, displays >1,000-fold selectivity over JAK1 and JAK2.

PF-05661014 is a potent, selective Nav1.3 inhibitor with IC50 of 0.26 uM, shows no activity for Nav1.7 (IC50>10 uM).

PF-05212377 (SAM-760, PF 5212377) is a potent and selective 5-HT6 receptor antagonist with potential therapy for the symptomatic treatment of mild to moderate Alzheimer's disease..

PF-04991532 (PF4991532) is a potent, hepatoselective Glucokinase (GK) activator with EC50 of 90±45 nM.

PF-04958242 is a novel potent, selctive, and orally-active AMPA receptor (AMPAR) positive allosteric modulator (PAM) with Ki of 170 nM, EC50 of 370 nM.

PF-04895162 (ICA-105665, PF 4895162) is an orally available agonist of neuronal Kv7 potassium channel, opens Kv7.2/7.3 and Kv7.3/7.5 potassium channels, also known as KCNQ2/3 and KCNQ3/5 channels.

PF-04701475 is a nove positive allosteric modulator of AMPA receptor, a prototype used to explore AMPAR-mediated pharmacology in vivo..

PF-04677490 is a potent, selective PDE1 inhibitor with IC50 of 21 nM for PDE1B.

PF-04634817 is a potent, orally bioavailble CCR2 and CCR5 chemokine receptor antagonist, for the treatment of diabetic nephropathies and diabetic macular oedema. .